Overview

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
To assess safety and tolerability after treatment with LEO 134310 cutaneous solution.
Phase:
Phase 1
Details
Lead Sponsor:
LEO Pharma
Treatments:
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate